About

AGC Biologics specializes in the development and production of therapeutic proteins, plasmid DNA, viral vectors, and genetically engineered cells for the biopharmaceutical industry. The company provides comprehensive services that cover the entire process from initial development to full-scale manufacturing, catering to clients ranging from small biotech firms to large pharmaceutical companies. Their facilities, located globally, adhere to strict quality regulations to ensure the safety and efficacy of the products. AGC Biologics differentiates itself by focusing on fast-track project capabilities, particularly for orphan drugs and rare diseases, which require quicker development timelines. The company's goal is to continuously innovate and enhance its manufacturing capabilities to support the advancement of new treatments in the biopharmaceutical sector.

Simplify's Take

What believers are saying

• Increased demand for cell and gene therapies boosts growth in the CDMO sector.
• Expansion of mRNA technology presents new opportunities for AGC Biologics.
• The global biopharmaceuticals market is expected to grow at a CAGR of 7.4%.

What critics are saying

• Restructuring and layoffs at the Colorado plant may disrupt operations.
• Turbulent economy in cell and gene therapy could impact financial performance.
• Expansion in Japan may strain resources and affect existing operations.

What makes AGC Biologics unique

• AGC Biologics specializes in therapeutic proteins, plasmid DNA, and viral vectors.
• The company offers fast-track project capabilities for orphan drugs and rare diseases.
• AGC Biologics operates globally with facilities in the U.S., Europe, and Asia.

Help us improve and share your feedback! Did you find this helpful?

YesNo